# Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

> **NCT05136898** · PHASE3 · COMPLETED · sponsor: **UroGen Pharma Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma
- Urothelial Carcinoma Bladder

## Interventions

- **DRUG:** UGN-102

## Key facts

- **NCT ID:** NCT05136898
- **Lead sponsor:** UroGen Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-02-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05136898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05136898, "Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05136898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*